Hydroxyzine (Atarax) for Short‑Term Anxiety Treatment in Adults

Hydroxyzine is not recommended as a first‑line treatment for anxiety disorders in adults; SSRIs (escitalopram or sertraline) combined with cognitive‑behavioral therapy represent the evidence‑based standard of care, while hydroxyzine may serve only as a short‑term adjunct in specific clinical scenarios.

Why Hydroxyzine Is Not First‑Line Therapy

Guideline Recommendations Prioritize SSRIs and CBT

Selective serotonin reuptake inhibitors—specifically escitalopram (10–20 mg/day) or sertraline (50–200 mg/day)—are the preferred first‑line pharmacologic agents for generalized anxiety disorder, panic disorder, and social anxiety disorder because they demonstrate robust efficacy (NNT ≈ 4.7), a favorable safety profile, and minimal risk of dependence. 1, 2
Individual cognitive‑behavioral therapy (12–20 sessions) has the highest level of evidence for anxiety disorders, with large effect sizes (Hedges g ≈ 1.0) and superior long‑term outcomes compared with pharmacotherapy alone. 1, 2
Combining an SSRI with individual CBT yields greater symptom reduction and functional improvement than either modality alone for moderate‑to‑severe anxiety, supported by moderate‑to‑high strength evidence. 1, 2

Limited Evidence Base for Hydroxyzine

A 2010 Cochrane systematic review concluded that "it is not possible to recommend hydroxyzine as a reliable first‑line treatment in GAD" due to high risk of bias in the included studies, small sample sizes, and insufficient data on long‑term efficacy and safety. 3
The five randomized controlled trials included in the Cochrane review enrolled only 884 participants total, and the studies did not report on all pre‑specified outcomes, limiting the strength of any recommendation. 3
Although hydroxyzine showed superiority over placebo (OR 0.30,95% CI 0.15–0.58), the high risk of bias and methodological limitations prevent endorsement as a first‑line agent. 3

FDA‑Approved Dosing and Indications

Approved Dose for Anxiety

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested, the FDA‑approved adult dose is 50–100 mg four times daily (total 200–400 mg/day). 4
When treatment is initiated by the intramuscular route, subsequent doses may be administered orally, and the dosage should be adjusted according to the patient's response to therapy. 4

Clinical Trial Dosing

Recent controlled trials have used a fixed dose of 50 mg daily (not 50 mg four times daily) and demonstrated superiority over placebo on all anxiety measures from the first week, with efficacy maintained throughout four weeks of treatment. 5
In a 1998 Russian open‑label study of 55 outpatients with generalized anxiety and somatoform disorders, a daily dose of 50 mg for 28 days resulted in a reduction of Hamilton Anxiety Scale scores by ≥10 points in 47 of 54 patients who completed the course. 6

Safety Precautions and Contraindications

QT Prolongation and Cardiac Risk

Cases of QT prolongation and Torsade de Pointes have been reported during post‑marketing use of hydroxyzine, with the majority occurring in patients with pre‑existing heart disease, electrolyte imbalances, or concomitant arrhythmogenic drug use. 4
Hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias. 4
Caution is recommended during concomitant use of drugs known to prolong the QT interval, including Class IA antiarrhythmics (quinidine, procainamide), Class III antiarrhythmics (amiodarone, sotalol), certain antipsychotics (ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (citalopram, fluoxetine), certain antibiotics (azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin), and others (pentamidine, methadone, ondansetron, droperidol). 4

Central Nervous System Depression

The potentiating action of hydroxyzine must be considered when the drug is used in conjunction with central nervous system depressants such as narcotics, non‑narcotic analgesics, and barbiturates; therefore, when CNS depressants are administered concomitantly with hydroxyzine, their dosage should be reduced. 4
Patients should be warned that drowsiness may occur and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. 4
Patients should also be advised against the simultaneous use of other CNS depressant drugs and cautioned that the effects of alcohol may be increased. 4

Acute Generalized Exanthematous Pustulosis (AGEP)

Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non‑follicular, sterile pustules arising within large areas of edematous erythema. 4
Discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre‑existing skin reactions, or any other sign of hypersensitivity; if signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. 4
Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross‑sensitivity. 4

Special Populations: Elderly Patients

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. 4
Sedating drugs may cause confusion and over‑sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely. 4
Elderly individuals exhibit reduced renal clearance and overall drug elimination, which narrows the therapeutic window and increases the risk of drug accumulation. 7
High doses of hydroxyzine can cause excessive anticholinergic burden, particularly when combined with other medications, increasing the risk of adverse drug reactions, cognitive impairment, and renal insufficiency in elderly patients. 7

Clinical Scenarios Where Hydroxyzine May Be Considered

Short‑Term Adjunctive Use

Benzodiazepines should be limited to short‑term adjunctive use (days to a few weeks) because of high risks of dependence, tolerance, cognitive impairment, and withdrawal syndromes; they are not first‑line or long‑term treatments for anxiety disorders. 2
By analogy, hydroxyzine may serve as a short‑term adjunct (days to a few weeks) in patients who require rapid anxiolysis while awaiting the therapeutic onset of an SSRI (which typically occurs by week 6), though this represents off‑label use without robust guideline endorsement. 1, 2

Patients with Contraindications to SSRIs

For patients who cannot tolerate SSRIs or SNRIs due to adverse effects (e.g., nausea, sexual dysfunction, activation) or who have contraindications (e.g., concurrent use of MAOIs, severe bleeding risk), hydroxyzine may be considered as an alternative anxiolytic, though buspirone (5 mg twice daily, titrated to 20 mg three times daily over 2–4 weeks) is generally preferred for chronic anxiety. 7, 8

Anxiety Associated with Organic Disease States

The FDA label specifically mentions hydroxyzine as an adjunct in organic disease states in which anxiety is manifested, such as cardiovascular disorders. 4
A 1999 Russian study of 55 outpatients with cardiovascular pathology (acute myocardial infarction, angina, postinfarction cardiosclerosis, essential hypertension) and comorbid anxiety found that hydroxyzine 50 mg daily for 28 days was well tolerated and safe, with a reduction in Hamilton Anxiety Scale scores by ≥10 points in 87% of patients who completed the course. 6

Common Pitfalls and Caveats

Do Not Use Hydroxyzine as Monotherapy for Chronic Anxiety

Hydroxyzine lacks the robust evidence base and guideline endorsement required for first‑line or long‑term treatment of anxiety disorders; SSRIs and CBT remain the standard of care. 1, 2, 3
Even though hydroxyzine is more effective than placebo, the high risk of bias in the included studies, the small number of studies, and the overall small sample size prevent recommendation as a reliable first‑line treatment in GAD. 3

Monitor for Sedation and Anticholinergic Effects

Hydroxyzine is associated with a higher rate of sleepiness/drowsiness than active comparators (benzodiazepines and buspirone) (OR 1.74,95% CI 0.86–3.53). 3
In a 1998 Russian open‑label study, transitory sleepiness occurred in 36% of patients, weakness in 18%, headache in 6%, changes in appetite and body mass in 6%, and slight mucosa dryness in 2%. 9

Avoid Polypharmacy in Elderly Patients

The combination of hydroxyzine with other anticholinergic agents in elderly patients dramatically increases the risk of delirium, falls, and cognitive impairment. 7
Never combine multiple anticholinergic agents in elderly patients, as the cumulative burden dramatically increases risk of delirium, falls, and cognitive impairment. 7

Screen for QT‑Prolonging Medications

Before prescribing hydroxyzine, obtain a medication history to identify concomitant use of QT‑prolonging drugs (antiarrhythmics, antipsychotics, antidepressants, antibiotics, methadone, ondansetron) and consider obtaining a baseline electrocardiogram in patients with cardiac risk factors. 4

Evidence‑Based Algorithm for Anxiety Treatment in Adults

Step 1: Initial Assessment

Rule out medical causes of anxiety (hyperthyroidism, caffeinism, hypoglycemia, asthma exacerbations, cardiac arrhythmias, other endocrine disorders) before initiating treatment. 1
Screen for comorbid depression using validated instruments (GAD‑7, PHQ‑9), as approximately 50–60% of adults with major depressive disorder also meet criteria for an anxiety disorder. 1

Step 2: First‑Line Treatment

Initiate an SSRI (escitalopram 5–10 mg daily or sertraline 25–50 mg daily) and titrate gradually every 1–2 weeks to a target dose of escitalopram 10–20 mg/day or sertraline 50–200 mg/day. 2
Refer for individual cognitive‑behavioral therapy (12–20 sessions) concurrently with pharmacotherapy, as combined treatment yields superior outcomes. 2
Counsel patients that statistically significant improvement may be seen by week 2, clinically meaningful improvement by week 6, and maximal benefit after ≥12 weeks of continuous therapy. 2

Step 3: If Inadequate Response After 8–12 Weeks

Switch to a different SSRI (e.g., from sertraline to escitalopram or vice‑versa) if response remains inadequate with good adherence. 2
Add individual CBT if it has not yet been implemented. 2
Consider an SNRI (venlafaxine XR 75–225 mg/day or duloxetine 60–120 mg/day) as a second‑line pharmacologic option. 2

Step 4: Short‑Term Adjunctive Anxiolysis (If Needed)

If severe acute symptomatic distress requires rapid anxiolysis while awaiting SSRI onset, consider a short‑term benzodiazepine (lorazepam 0.5–1 mg as needed, maximum 2 mg/day for days to a few weeks) or, alternatively, hydroxyzine 25–50 mg as needed (maximum 200–400 mg/day per FDA label, though clinical trials have used 50 mg daily) for short‑term use only. 2, 4, 5
Discontinue the adjunctive anxiolytic after 2–4 weeks to avoid dependence, tolerance, and cognitive impairment. 2

Step 5: Maintenance and Relapse Prevention

Continue effective medication for at least 9–12 months after remission to reduce relapse risk. 2
Taper the medication over 10–14 days (or longer) to avoid withdrawal, especially with short‑half‑life SSRIs. 2

Summary of Hydroxyzine's Role

Hydroxyzine is FDA‑approved for symptomatic relief of anxiety at a dose of 50–100 mg four times daily (200–400 mg/day total), though clinical trials have used lower doses (50 mg daily). 4, 5
Hydroxyzine is not recommended as a first‑line treatment for anxiety disorders due to limited evidence quality, lack of guideline endorsement, and the availability of superior alternatives (SSRIs + CBT). 3, 2
Hydroxyzine may serve as a short‑term adjunct (days to a few weeks) in specific scenarios, such as patients awaiting SSRI onset, those with contraindications to SSRIs, or those with anxiety associated with organic disease states. 4, 6, 5
Key safety precautions include monitoring for QT prolongation, avoiding concomitant CNS depressants, discontinuing at the first sign of skin rash (AGEP risk), and using cautious dosing in elderly patients. 4

Is Atarax (hydroxyzine) appropriate for short‑term anxiety treatment in adults, and what dosing and safety precautions are recommended?

Help us tailor your experience